Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (NASDAQ:INSM) and Grifols SA (NASDAQ:GRFS).
Insmed (INSM)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Insmed, with a price target of $40. The company’s shares closed on Friday at $20.22, close to its 52-week low of $18.64.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 14.5% and a 64.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Voyager Therapeutics Inc.
Insmed has an analyst consensus of Moderate Buy, with a price target consensus of $42.80, representing an 111.7% upside. In a report issued on September 18, H.C. Wainwright also maintained a Buy rating on the stock with a $43 price target.
.
See today’s analyst top recommended stocks >>
Grifols SA (GRFS)
Morgan Stanley analyst David Lewis maintained a Sell rating on Grifols SA today and set a price target of $20. The company’s shares closed on Friday at $21.37.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 16.2% and a 75.0% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Intuitive Surgical, and Haemonetics Corp.
Grifols SA has an analyst consensus of Moderate Sell, with a price target consensus of $20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
